Prognosis
Merck Treatment Inhibits Covid Variants, Early Data Show
This article is for subscribers only.
Merck & Co.’s Covid-19 antiviral drug, molnupiravir, appears to inhibit several major variants of the virus, including the highly contagious delta strain, according to early stage data presented by the company at an infectious disease conference early Wednesday.
The findings came out of laboratory research pitting the experimental drug against the variants in cell culture. Further research may be needed to confirm the results in human testing.